- Home
- MCN vs NOTV Comparison
MCN vs NOTV Comparison
Compare MCN & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCN
- NOTV
- Stock Information
- Founded
- MCN 2004
- NOTV 1974
- Country
- MCN Canada
- NOTV United States
- Employees
- MCN N/A
- NOTV N/A
- Industry
- MCN
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- MCN
- NOTV Health Care
- Exchange
- MCN Nasdaq
- NOTV Nasdaq
- Market Cap
- MCN 115.9M
- NOTV 137.5M
- IPO Year
- MCN N/A
- NOTV 1997
- Fundamental
- Price
- MCN $6.09
- NOTV $2.69
- Analyst Decision
- MCN
- NOTV Strong Buy
- Analyst Count
- MCN 0
- NOTV 1
- Target Price
- MCN N/A
- NOTV $5.00
- AVG Volume (30 Days)
- MCN 52.9K
- NOTV 716.3K
- Earning Date
- MCN 01-01-0001
- NOTV 05-07-2025
- Dividend Yield
- MCN 9.96%
- NOTV N/A
- EPS Growth
- MCN N/A
- NOTV N/A
- EPS
- MCN N/A
- NOTV N/A
- Revenue
- MCN N/A
- NOTV $480,402,000.00
- Revenue This Year
- MCN N/A
- NOTV $5.57
- Revenue Next Year
- MCN N/A
- NOTV $5.23
- P/E Ratio
- MCN N/A
- NOTV N/A
- Revenue Growth
- MCN N/A
- NOTV N/A
- 52 Week Low
- MCN $6.69
- NOTV $1.15
- 52 Week High
- MCN $8.60
- NOTV $6.48
- Technical
- Relative Strength Index (RSI)
- MCN 63.79
- NOTV 56.91
- Support Level
- MCN $6.03
- NOTV $2.55
- Resistance Level
- MCN $6.11
- NOTV $3.32
- Average True Range (ATR)
- MCN 0.07
- NOTV 0.33
- MACD
- MCN -0.00
- NOTV 0.05
- Stochastic Oscillator
- MCN 90.48
- NOTV 53.68
About MCN Madison Covered Call & Equity Strategy Fund
XAI Madison Equity Premium Income Fund is an investment management company. The Fund invests in an actively managed equity portfolio comprised of individual stocks and covered call options. The Fund's primary investment objective is to provide high level of current income and gains, with a secondary objective of capital appreciation.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.